1. Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial. Issue 9 (September 2018) Authors: Cramer, Paula; von Tresckow, Julia; Bahlo, Jasmin; Robrecht, Sandra; Langerbeins, Petra; Al-Sawaf, Othman; Engelke, Anja; Fink, Anna-Maria; Fischer, Kirsten; Tausch, Eugen; Seiler, Till; Fischer von Weikersthal, Ludwig; Hebart, Holger; Kreuzer, Karl-Anton; Böttcher, Sebastian; Ritgen, Matthias; K... Journal: Lancet oncology Issue: Volume 19:Issue 9(2018) Page Start: 1215 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Efficacy and safety of obinutuzumab combined with fludarabine and cyclophosphamide (FCG) or bendamustine (BG) in relapsed or refractory CLL patients followed by maintenance therapy with obinutuzumab for responding patients. Issue 2 (28th January 2023) Authors: Kutsch, Nadine; Holmes, Emily Eva; Robrecht, Sandra; Schüler, Gudrun; Vehling-Kaiser, Ursula; Decker, Thomas; Müller-Hagen, Sigrun; Heinisch, Karin; Böttcher, Sebastian; Ritgen, Matthias; Kreuzer, Karl-Anton; Stilgenbauer, Stephan; Fink, Anna Maria; Fischer, Kirsten; Eichhorst, Barbara; Hallek, M... Journal: Leukemia & lymphoma Issue: Volume 64:Issue 2(2023) Page Start: 478 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. KIR2DS1–HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials. Issue 2 (February 2022) Authors: Kaddu-Mulindwa, Dominic; Altmann, Bettina; Robrecht, Sandra; Ziepert, Marita; Regitz, Evi; Tausch, Eugen; Held, Gerhard; Poeschel, Viola; Lesan, Vadim; Bittenbring, Joerg Thomas; Thurner, Lorenz; Pfreundschuh, Michael; Christofyllakis, Konstantinos; Truemper, Lorenz; Loeffler, Markus; Schmitz, No... Journal: Lancet Issue: Volume 9:Issue 2(2022) Page Start: e133 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Issue 10 (October 2017) Authors: Fink, Anna Maria; Bahlo, Jasmin; Robrecht, Sandra; Al-Sawaf, Othman; Aldaoud, Ali; Hebart, Holger; Jentsch-Ullrich, Kathleen; Dörfel, Steffen; Fischer, Kirsten; Wendtner, Clemens-Martin; Nösslinger, Thomas; Ghia, Paolo; Bosch, Francesc; Kater, Arnon P; Döhner, Hartmut; Kneba, Michael; Kreuzer, Ka... Journal: Lancet Issue: Volume 4:Issue 10(2017) Page Start: e475 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG). Issue 1 (February 2020) Authors: Kutsch, Nadine; Bahlo, Jasmin; Robrecht, Sandra; Franklin, Jeremy; Zhang, Can; Maurer, Christian; De Silva, Nisha; Lange, Elisabeth; Weide, Rudolf; Kiehl, Michael G.; Sökler, Martin; Schlag, Rudolf; Vehling-Kaiser, Ursula; Köchling, Georg; Plöger, Christoph; Gregor, Michael; Plesner, Torben; Herl... Journal: HemaSphere Issue: Volume 4:Issue 1(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study. Issue 36 (20th December 2021) Authors: Al-Sawaf, Othman; Zhang, Can; Lu, Tong; Liao, Michael Z.; Panchal, Anesh; Robrecht, Sandra; Ching, Travers; Tandon, Maneesh; Fink, Anna-Maria; Tausch, Eugen; Schneider, Christof; Ritgen, Matthias; Böttcher, Sebastian; Kreuzer, Karl-Anton; Chyla, Brenda; Miles, Dale; Wendtner, Clemens-Martin; Eich... Journal: Journal of clinical oncology Issue: Volume 39:Issue 36(2021) Page Start: 4049 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine–mitoxantrone–cyclophosphamide–alemtuzumab induction followed by alemtuzumab maintenance. Issue 3 (23rd February 2019) Authors: Pflug, Natali; Cramer, Paula; Robrecht, Sandra; Bahlo, Jasmin; Westermann, Anne; Fink, Anna-Maria; Schrader, Alexandra; Mayer, Petra; Oberbeck, Sebastian; Seiler, Till; Zenz, Thorsten; Dürig, Jan; Kreuzer, Karl-Anton; Stilgenbauer, Stephan; Eichhorst, Barbara; Hallek, Michael; Herling, Marco; Hop... Journal: Leukemia & lymphoma Issue: Volume 60:Issue 3(2019) Page Start: 649 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib. Issue 2 (9th October 2017) Authors: Wolf, Christine; Garding, Angela; Filarsky, Katharina; Bahlo, Jasmin; Robrecht, Sandra; Becker, Natalia; Zucknick, Manuela; Rouhi, Arefeh; Weigel, Anja; Claus, Rainer; Weichenhan, Dieter; Eichhorst, Barbara; Fischer, Kirsten; Hallek, Michael; Kuchenbauer, Florian; Plass, Christoph; Döhner, Hartmu... Journal: International journal of cancer Issue: Volume 142:Issue 2(2018) Page Start: 322 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Obinutuzumab in Allogeneic Transplantation for CLL and Richter's Transformation in the Age of Targeted Therapies. Issue 12 (12th December 2021) Authors: Pflug, Natali; Chakupurakal, Geothy; Fink, Anna-Maria; Robrecht, Sandra; Herling, Marco; Cramer, Paula; Holtick, Udo; Theurich, Sebastian; Schetelig, Johannes; Fischer, Kirsten; Ritgen, Matthias; Scheid, Christof; Eichhorst, Barbara; Dreger, Peter; Hallek, Michael; von Bergwelt-Baildon, Michael Other Names: other. Journal: HemaSphere Issue: Volume 5:Issue 12(2021) Page Start: e664 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial. Issue 10 (October 2022) Authors: Cramer, Paula; Fürstenau, Moritz; Robrecht, Sandra; Giza, Adam; Zhang, Can; Fink, Anna-Maria; Fischer, Kirsten; Langerbeins, Petra; Al-Sawaf, Othman; Tausch, Eugen; Schneider, Christof; Schetelig, Johannes; Dreger, Peter; Böttcher, Sebastian; Kreuzer, Karl-Anton; Schilhabel, Anke; Ritgen, Matthia... Journal: Lancet Issue: Volume 9:Issue 10(2022) Page Start: e745 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗